China’s NMPA approves AstraZeneca and Merck’s Lynparza for ovarian cancer
A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),